Tag: de novo antibody design

Chai Discovery’s license agreement with Pfizer goes beyond standard platform access: Pfizer gets a custom Chai-3 model trained on its own proprietary data, embedded inside its discovery workflows. The arrangement reflects a broader shift in AI drug discovery, where competitive advantage is moving from model architecture toward the proprietary training data that makes a model… Read more